The $NKLA response is typical, but just so poor. Seriously, these crisis communication firms are stealing their clients’ money. First mistake is to play the ad hominem card - and hard by repeatedly saying “manipulation”. The big problem is company / Milton credibility... 1/
But the “rebuttals” are countering statements of fact (e.g., was not a $NKLA inverter) with safe harbor protected fluff (working hard on own inverters). Effectively, this release confirms the statements of FACT. It’s taking issue w/ @HindenburgRes OPINIONS from those facts... 2/
So repeatedly accusing @HindenburgRes of manipulation while confirming facts and arguing opinions is really discrediting of $NKLA. In my experience, investors see through this. So net-net company still has same credibility issue. Esp when NKLA is parsing language re “in motion”3/
Also going ad hominem just fires up the short seller more - every time. How should company have responded? Focus on milestones achieved since these events, announce concrete steps to improve transparency, show contrition, & then say @HindenburgRes has drawn wrong conclusions
By the way, MW / I have no position in NKLA & have never had one. For those of you strapping on your tinfoil hats thinking I’m trying to “hit” the stock to make money, go ahead and take them off. I’m an activist short seller expressing an opinion on these events - nothing more.
• • •
Missing some Tweet in this thread? You can try to
force a refresh
MW is short $KDNY. We believe its lead drug, atrasentan, will never get FDA approval. Trial data have shown it's a) inefficacious and b) increases cardiac and mortality risks. AbbVie and KDNY have manipulated and misrepresented trial data to conceal muddywatersresearch.com/research/kdny/…
Atrasentan shows no sign of renal repair. Trial data show in our view $KDNY biomarker effects are hemodynamic effect (dilution), which lowered UACR. Post treatment, UACR converged with placebo. Systolic BP converged during treatment. Anemia stat sig higher muddywatersresearch.com/research/kdny/…
AbbVie and now $KDNY obscure the trial data by a) distorting time periods on charts, b) using a composite endpoint that combines negative and positive outcomes, and c) cherry picking data to give the impressions of efficacy and safety muddywatersresearch.com/research/kdny/…
In June 2018, MW issued a report on $TAL “A Real Business With Fake Financials.” In June 2020, we reported on $GOTU concluding it’s a fake business w/ fake financials. What we see today isn’t directly a result of the fraud, but it is indirectly a result. 1/
The system that allows such frauds to persist and flourish is a highly corrupt system run by a highly corrupt autocratic government. A government that can’t be trusted - especially by foreigners who thought they were *beneficiaries* of this system. You were wrong. 2/
That is narcissism typical of western investors in China. It was clear once the CCP made the choice in 2012 to protect the frauds (e.g., through protecting auditors from SEC) that foreign capital was allowed to receive returns at the pleasure of the CCP, but that when push came…
MW is short $LMND bc it has an egregious security vulnerability & utterly failed to secure customer PII. Customer PII has actually been indexed by Google and other search engines. Many customer accounts can be accessed without any authentication at all! muddywatersresearch.com/research/lmnd/…
$LMND should immediately take its site, API, and app offline to remediate. Breach seemingly existed since 7/2020, LMND must investigate scope of breach & inform all potentially affected customers. We think it’s likely a breach has occurred. muddywatersresearch.com/research/lmnd/…
$LMND security vuln is so obvious we *accidentally* discovered it during fundamental research & can be detected by industry standard app costing $400 / year. LMND could be liable under GDPR, NY fin service regs & CA Consumer Privacy Act muddywatersresearch.com/research/lmnd/…
MW is short $XL bc it's middle of the fairway SPAC garbage. The real "green" tech is duping investors and customers through exaggerations, half truths, and mistruths. Claimed backlog is greatly exaggerated, purported customers haven't ordered in years. muddywatersresearch.com/research/xl/mw…
Former $XL salespeople tell of being forced to exaggerate pipelines, esp when the board was going to meet. "A minimum of four times a year [manager] would exaggerate my pipeline substantially to report to the board." muddywatersresearch.com/research/xl/mw…
Customer ROIs actually r negative. Former $XL employee describes a customer gain as "a blatant lie". 18 of 33 customers featured in investor deck reportedly r inactive. Reorder rate only ~10%. Tod Hynes y'day deflected @jimcramer customer question on this. muddywatersresearch.com/research/xl/mw…
I'm seeing a lot of people decry de-platforming WSB, Trump, etc. Personally, I have mixed feelings on this & there are no clear answers. First, this isn't a 1st Amendment issue. Public property must permit speech, subject to reasonable time, manner, and place restrictions. 1/
However, businesses obviously don't need to allow demonstrators. A privately-owned business shutting down speakers or categories of speech is consistent with THEIR 1st Amendment rights. Then the response becomes "These platforms are too powerful". Yes, BUT... 2/
WE gave them this power. We give our deepest, darkest secrets to Big Tech. It's not their fault. It's our fault. But putting that to the side, I am a huge believer in "The Marketplace of Ideas", which holds that good ideas ("truth") makes its way to the top; bad ideas sink 3/
MW is short $INO. Stock ramped on hype around Covid vaccine. A recent court decision against INO makes it clear that INO lacks manufacturing capacity to get remotely near purported goal of 1 mm doses in ‘20 & 100 mm in ’21 1/ drive.google.com/file/d/1K4wnKD…
$INO sued its primary supplier, VGXI, for a temp injunction to force transfer of manufacturing technology to ~10 manufacturers. VGXI refuses to transfer the technology. Absent transfer, capacity doesn't exist. Injunction denied. 2/ drive.google.com/file/d/1izYYO5…drive.google.com/file/d/167XCaC…
We cannot forsee $INO competing w/ the 5 Operation Warp Speed vaccine candidates. (INO is NOT one of the candidates.) At best, INO either has to wait for final judgment (likely too long) or pay VGXI money INO likely doesn’t have. Our favorite part of temp injunction decision 3/